Duloxetine efficacy for major depressive disorder in male vs. female patients: Data from 7 randomized, double-blind, placebo-controlled trials

Journal of Clinical Psychiatry

Volumn 67, Issue 5, 2006, Pages 761-770

  Kornstein, Susan G ^a   Wohlreich, Madelaine M ^b   Mallinckrodt, Craig H ^b   Watkin, John G ^b   Stewart, Donna E ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENDER BIAS; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 33745428445     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0510     Document Type: Article

References (62)

1. Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am 2003;26:581-594
2. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74:5-13
3. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
4. Kornstein SG. Gender differences in depression: implications for treatment. J Clin Psychiatry 1997;58(suppl 15):12-18
5. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994;151:979-986
6. Fava M, Abraham M, Alpert J, et al. Gender differences in Axis I comorbidity among depressed outpatients. J Affect Disord 1996;38:129-133
7. Isometsa ET, Henriksson MM, Aro HM, et al. Suicide in major depression. Am J Psychiatry 1994;151:530-536
8. Angst J, Dobler-Mikola A. Do the diagnostic criteria determine the sex ratio in depression? J Affect Disord 1984;7:189-198
9. Kornstein SG, Sloan DM, Thase ME. Gender-specific differences in depression and treatment response. Psychopharmacol Bull 2002;36 (4 suppl 3):99-112
10. Silverstein B. Gender differences in the prevalence of somatic versus pure depression: a replication. Am J Psychiatry 2002;159:1051-1052
11. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in chronic major and double depression. J Affect Disord 2000;60:1-11
12. Khan AA, Gardner CO, Prescott CA, et al. Gender differences in the symptoms of major depression in opposite-sex dizygotic twin pairs. Am J Psychiatry 2002;159:1427-1429
13. Dawkins K, Potter WZ. Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. Psychopharmacol Bull 1991;27:417-426
14. Frackiewicz EJ, Sramek JJ, Cutler NR. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 2000;34:80-88
15. Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992;149:587-595
16. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239
17. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997;33:235-241
18. Bies RR, Bigos KL, Pollock BG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. J Gend Specif Med 2003;6:12-20
19. Kornstein SG, Wojcik BA. Gender effects in the treatment of depression. Psychiatr Clin North Am 2000;7:23-57
20. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996;123:315-319
21. Moody JP, Tait AC, Todrick A. Plasma levels of imipramine and desmethylimipramine during therapy. Br J Psychiatry 1967;113:183-193
22. Preskom SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry 1985;46:276-277
23. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996;16:19-25
24. Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003;160:1643-1650
25. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32(suppl 1):22-30
26. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990;19:241-255
27. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987;42:193-200
28. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984;35:792-797
29. Jensvold MF, Reed K, Jarrett DB, et al. Menstrual cycle-related depressive symptoms treated with variable antidepressant dosage. J Womens Health 1992;1:109-115
30. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-1542
31. Hamilton JA, Lloyd C, Alagna SW, et al. Gender, depressive subtypes, and gender-age effects on antidepressant response: hormonal hypotheses. Psychopharmacol Bull 1984;20:475-480
32. Hamilton JA, Grant M, Jensvold MF. Sex and treatment of depression. In: Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women: Sex, Gender, and Hormones. Washington, DC: American Psychiatric Association Press; 1996:241-260
33. Glassman AH, Perel JM, Shostak M, et al. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977; 34:197-204
34. Coppen A, Whybrow PC, Noguera R, et al. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972;26:234-241
35. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445-1452
36. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986;17:87-95
37. Haykal RF, Akiskal HS. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. J Clin Psychiatry 1999;60:508-518
38. Martenyi F, Dossenbach M, Mraz K, et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001;11:227-232
39. Joyce PR, Mulder RT, Luty SE, et al. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 2003;108:20-23
40. Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002;36:384-391
41. Lewis-Hall FC, Wilson MG, Tepner RG, et al. Fluoxetine vs tricyclic antidepressants in women with major depressive disorder. J Womens Health 1997;6:337-343
42. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-877
43. Quitkin FM, Stewart JW, McGrath PJ, et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry 2002;159:1848-1854
44. Parker G, Parker K, Austin MP, et al. Gender differences in response to differing antidepressant drug classes: two negative studies. Psychol Med 2003;33:1473-1477
45. Scheibe S, Preuschhof C, Cristi C, et al. Are there gender differences in major depression and its response to antidepressants? J Affect Disord 2003;75:223-235
46. Wohlfarth T, Storosum JG, Elferink AJ, et al. Response to tricyclic antidepressants: independent of gender? Am J Psychiatry 2004;161:370-372
47. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231
48. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399
49. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
50. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
51. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53
52. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-132
53. Stewart DE, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord. In press
54. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
55. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
56. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:313-331
57. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med 1994;23:129-138
58. DeLoach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102-106
59. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992;22:307-319
60. Meana M. The meeting of pain and depression: comorbidity in women. Can J Psychiatry 1998;43:893-899
61. Wilcox CS, Cohn JB, Linden RD, et al. Predictors of placebo response: a retrospective analysis. Psychopharmacol Bull 1992;28:157-162
62. Casper RC, Tollefson GD, Nilsson ME. No gender differences in placebo responses of patients with major depressive disorder. Biol Psychiatry 2001;49:158-160